116 related articles for article (PubMed ID: 29744290)
1. Identification of small-molecule elastase inhibitors as antagonists of IL-36 cytokine activation.
Sullivan GP; Davidovich PB; Sura-Trueba S; Belotcerkovskaya E; Henry CM; Clancy DM; Zinoveva A; Mametnabiev T; Garabadzhiu AV; Martin SJ
FEBS Open Bio; 2018 May; 8(5):751-763. PubMed ID: 29744290
[TBL] [Abstract][Full Text] [Related]
2. Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice.
Hernández-Santana YE; Leon G; St Leger D; Fallon PG; Walsh PT
Life Sci Alliance; 2020 Apr; 3(4):. PubMed ID: 32086318
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis.
Boutet MA; Nerviani A; Lliso-Ribera G; Lucchesi D; Prediletto E; Ghirardi GM; Goldmann K; Lewis M; Pitzalis C
Rheumatology (Oxford); 2020 Apr; 59(4):828-838. PubMed ID: 31504934
[TBL] [Abstract][Full Text] [Related]
4. IκBζ is a key transcriptional regulator of IL-36-driven psoriasis-related gene expression in keratinocytes.
Müller A; Hennig A; Lorscheid S; Grondona P; Schulze-Osthoff K; Hailfinger S; Kramer D
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10088-10093. PubMed ID: 30224457
[TBL] [Abstract][Full Text] [Related]
5. IL-36 Promotes Systemic IFN-I Responses in Severe Forms of Psoriasis.
Catapano M; Vergnano M; Romano M; Mahil SK; Choon SE; Burden AD; Young HS; Carr IM; Lachmann HJ; Lombardi G; Smith CH; Ciccarelli FD; Barker JN; Capon F
J Invest Dermatol; 2020 Apr; 140(4):816-826.e3. PubMed ID: 31539532
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil extracellular traps are induced in a psoriasis model of interleukin-36 receptor antagonist-deficient mice.
Watanabe S; Iwata Y; Fukushima H; Saito K; Tanaka Y; Hasegawa Y; Akiyama M; Sugiura K
Sci Rep; 2020 Nov; 10(1):20149. PubMed ID: 33214582
[TBL] [Abstract][Full Text] [Related]
7. Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis.
Benezeder T; Painsi C; Patra V; Dey S; Holcmann M; Lange-Asschenfeldt B; Sibilia M; Wolf P
Elife; 2020 Jun; 9():. PubMed ID: 32484435
[TBL] [Abstract][Full Text] [Related]
8. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses.
Mercurio L; Failla CM; Capriotti L; Scarponi C; Facchiano F; Morelli M; Rossi S; Pagnanelli G; Albanesi C; Cavani A; Madonna S
PLoS One; 2020; 15(4):e0222969. PubMed ID: 32352958
[TBL] [Abstract][Full Text] [Related]
9. IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis.
Goldstein JD; Bassoy EY; Caruso A; Palomo J; Rodriguez E; Lemeille S; Gabay C
Life Sci Alliance; 2020 Jun; 3(6):. PubMed ID: 32345660
[TBL] [Abstract][Full Text] [Related]
10. TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency.
Fukushima H; Iwata Y; Watanabe S; Saito K; Tanaka Y; Hasegawa Y; Akiyama M; Sugiura K
Sci Rep; 2020 Jan; 10(1):734. PubMed ID: 31959814
[TBL] [Abstract][Full Text] [Related]
11. The Significance of IL-36 Hyperactivation and IL-36R Targeting in Psoriasis.
Madonna S; Girolomoni G; Dinarello CA; Albanesi C
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284527
[TBL] [Abstract][Full Text] [Related]
12. Small Molecule IL-36γ Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis.
Todorović V; Su Z; Putman CB; Kakavas SJ; Salte KM; McDonald HA; Wetter JB; Paulsboe SE; Sun Q; Gerstein CE; Medina L; Sielaff B; Sadhukhan R; Stockmann H; Richardson PL; Qiu W; Argiriadi MA; Henry RF; Herold JM; Shotwell JB; McGaraughty SP; Honore P; Gopalakrishnan SM; Sun CC; Scott VE
Sci Rep; 2019 Jun; 9(1):9089. PubMed ID: 31235749
[TBL] [Abstract][Full Text] [Related]
13. Neutrophil Extracellular Traps Promote Inflammatory Responses in Psoriasis via Activating Epidermal TLR4/IL-36R Crosstalk.
Shao S; Fang H; Dang E; Xue K; Zhang J; Li B; Qiao H; Cao T; Zhuang Y; Shen S; Zhang T; Qiao P; Li C; Gudjonsson JE; Wang G
Front Immunol; 2019; 10():746. PubMed ID: 31024570
[TBL] [Abstract][Full Text] [Related]
14. IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential.
Boutet MA; Nerviani A; Pitzalis C
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871134
[TBL] [Abstract][Full Text] [Related]
15. IL-36γ regulates mediators of tissue homeostasis in epithelial cells.
Heath JE; Scholz GM; Veith PD; Reynolds EC
Cytokine; 2019 Jul; 119():24-31. PubMed ID: 30856602
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin G cleaves and activates IL-36γ and promotes the inflammation of psoriasis.
Guo J; Tu J; Hu Y; Song G; Yin Z
Drug Des Devel Ther; 2019; 13():581-588. PubMed ID: 30804664
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Chemokine Receptor Inhibition in Treating IL-36α-Induced Psoriasiform Inflammation.
Campbell JJ; Ebsworth K; Ertl LS; McMahon JP; Wang Y; Yau S; Mali VR; Chhina V; Kumamoto A; Liu S; Dang T; Newland D; Charo IF; Zhang P; Schall TJ; Singh R
J Immunol; 2019 Mar; 202(6):1687-1692. PubMed ID: 30718298
[TBL] [Abstract][Full Text] [Related]
18. IL-36 Signaling Is Essential for Psoriatic Inflammation through the Augmentation of Innate Immune Responses.
Ohko K; Nakajima K; Kataoka S; Takaishi M; Sano S
J Invest Dermatol; 2019 Jun; 139(6):1400-1404. PubMed ID: 30571968
[No Abstract] [Full Text] [Related]
19. IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.
Mercurio L; Morelli M; Scarponi C; Eisenmesser EZ; Doti N; Pagnanelli G; Gubinelli E; Mazzanti C; Cavani A; Ruvo M; Dinarello CA; Albanesi C; Madonna S
Cell Death Dis; 2018 Oct; 9(11):1104. PubMed ID: 30377293
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
